0224 GMT - Medical-imaging tech-provider Pro Medicus needs to improve the visibility of its business pipeline or demonstrate an ability to speed up market-share gains in order to turn Macquarie analysts more positive on the stock. The analysts moderate their market-share assumption to 10% in fiscal 2027, from 11% previously. They say to clients in a note that they have largely factored in the announcement of further contract wins and renewals. Pro Medicus has yet to demonstrate material uptake of opportunities in adjacent specialities, such as cardiology, they say, adding that they see the stock as fairly valued following a recent de-rate. Macquarie trims its target price by 0.4% to A$257.40, maintaining a neutral rating. Shares are down 7.6% at A$210.405. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 26, 2025 22:24 ET (02:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。